AstraZeneca AZN announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) rendered ...

Interim results from the global MATTERHORN study mark the first time an immunotherapy has demonstrated statistically ...

In addition to its indications in lung cancers, IMFINZI is approved in combination with chemotherapy (gemcitabine plus cisplatin) in locally advanced or metastatic biliary tract cancer and in ...

Imfinzi was first approved for treating bladder cancer in 2017. Its label was later expanded to include more indications including unresectable NSCLC, small-cell lung cancer, metastatic NSCLC ...

Home page Seeking Alpha - Power to Investors About Premium Explore Alpha Picks Home ...

Three more fake batches of the cancer immunotherapy have been encountered in Iran and Türkiye, warns the agency.

Imfinzi is already approved for unresectable ... Sales momentum for the drug is still good, however, fuelled by a lengthening list of indications in other cancers, including most recently primary ...

Immune checkpoint blockade involves drugs that we call PD-1 or PDL-1 inhibitors, and Imfinzi is a PDL-1 inhibitor. These drugs have been used alone in various indications and also combined with ...

It's a disappointing result for AZ, which is trying to extend the uses of Imfinzi from its current approved indications in non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC ...